Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Remdesivir: How does the drug treat coronavirus and is it available in the UK?

US says it has secured 100 per cent of drug-makers’ supply for July

Matt Mathers
Wednesday 01 July 2020 13:28 BST
0Comments
US authorises use of anti-viral drug remdesivir for coronavirus patients

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Health officials in the US have announced that the Trump administration has bought almost the entire world’s stock of the Covid-19 drug remdesivir.

According to the country’s Department of Health and Human Services (HHS) , “this represents 100 per cent of Gilead’s (the company that exclusively manufactures the drug) projected production for July”.

Experts and campaigners have condemned the move which means that other countries across the globe will struggle to obtain supplies of the treatment.

But what is remdesivir, how does it work in treating Covid-19 and is it available to patients in the UK?

What is remdesivir?

Remdesivir is an experimental antiviral drug first created and developed by the biopharmaceutical company Gilead Sciences in 2009.

It was originally created to treat hepatitis C but proved ineffective. Since then, it has been used to treat Ebola but didn’t work well against that disease either.

Despite this, remdesivir later showed promise in fighting SARS and MERS — illnesses caused by coronaviruses — in animal studies, which is why researchers thought remdesivir might help fight the new coronvirus.

Remdesivir is only one of two drugs approved by health authorities in the UK to treat Covid-19, the other being dexamethasone.

The cost is around $3,200 (£2,500) per treatment of six doses, according to the US government statement.

How does remdesivir treat Covid-19?

Remdesivir is designed to block some viruses – including the new coronavirus – from duplicating themselves and therefore overwhelming the host’s immune system.

The drug works differently to other antibody-based treatments or vaccines, which are designed to help a person’s immune system identify and eliminate pathogens.

Despite its ability to shorten the recovery times (by around four days) of some coronavirus patients, remdesivir has not been found to significantly improve an individual’s chances of surviving the disease.

The drug is administered intravenously and is most effective when it is given to a patient early.

Is remdesivir available to all Covid-19 patients in the UK?

After being approved for use in the UK at the end of May, health officials announced that remdesivir will be available to “selected NHS patients” only.

“The drug will be used in adults and adolescents hospitalised with severe Covid-19 infection who meet clinical criteria suggesting they have the greatest likelihood of benefiting,” the department of health said in a statement.

This means that remdesirvir will only be available to the most sick patients.

The decision by the US on Tuesday to stockpile remdesivir could make it more difficult for hospitals in the UK to procure the drug.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

0Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in